Search PubMed⌕ Search

Biomedical subjects

T E Mandel

Publications and source records attributed to T E Mandel.

At least 91 records · Page 5Linked to original sources

Fetal pancreas transplantation in non-obese diabetic (NOD) mice. A comparison of iso-, allo- and xenografts.

Prediabetic NOD/Wehi male mice aged 100 days were each transplanted under the renal capsule with three pieces of organ-cultured fetal pancreas; an isograft of NOD pancreas, an allograft of CBA (H-2k) pancreas, and a xenograft of fetal pig tissue. Groups of mice were given immunosuppression on days -1, 0 and +1 relative to transplantation with either an anti-CD4 monoclonal antibody (MAb, GK1.5), with or without a low dose (50 mg/kg IP) of cyclosporin A (CsA), with CsA alone or phosphate buffered saline in non-immunosuppressed controls. Flow cytometric analysis showed that CD4+ cells were severely depleted in mice that had been given GK1.5 11 days previously, but these cells slowly recovered to 35% of control levels by day 28, and 70% by day 56. The xenografted islets were slowly destroyed in the MAb-treated mice, at a rate which was slower than rejection of the allografts. At 28 days, when the allografts were severely affected, the xenografts were generally well preserved. The immunosuppression also did not stop mononuclear cell infiltration of the isografts. However, by 56 days all xenografts and most allografts were totally destroyed, and the isografts were infiltrated to an extent similar to that present in the pancreas. These results suggest that xenogeneic islets are no more and possibly even less immunogeneic than MHC-mismatched allografts, and are only slowly rejected after a peri-transplant period of immunosuppression used to transiently deplete CD4+ cells. However, the transient immunisuppression used did not result in indefinite xenograft survival suggestive of immunological tolerance.

Animals↗

Transplantation: 1988.

The issue of transplantation always holds a fascination for immunobiologists. A recent international congress' provided a forum for discussing new advances in this field, such as in xenotransplantation, central nervous system grafts, tolerance induction and the contribution of molecular biological approaches to transplantation immunobiology.

Animals↗

Tolerance to aggregated human IgG but not ovalbumin can be induced by concurrent administration of depleting or non-depleting anti-L3T4 monoclonal antibodies.

Tolerance to soluble antigens has previously been shown to occur in mice if anti-L3T4 monoclonal antibody (MoAb) is administered at the time of antigen exposure. The process of tolerance induction may require the depletion of L3T4+ cells or it may be due to down-regulation or negative signalling of L3T4+ cells. We compared the effects of L3T4+ cell depletion and L3T4 antigen blockade at the time of primary antigen challenge on long-term humoral responses. Anti-L3T4 MoAb GK1.5 (IgG2b) and H129.19 (IgG2a) were used to deplete or block, respectively, L3T4+ cells. Following a short course of MoAb and antigen challenge with both aggregated human IgG (ag-HGG) and ovalbumin (OVA) in each mouse, primary response titres to each antigen in both MoAb treated groups were approximately 1:10(2) compared with approximately 1:10(5) in control mice. Repeated antigen challenge significantly increased the anti-OVA titre in both MoAb treated groups and by 150 days they were similar to controls. However, anti-HGG titres did not increase significantly in either of the MoAb treated groups. Thus either depletion of peripheral L3T4+ cells, or blockade of the L3T4 antigen without depletion of peripheral L3T4+ cells, can invoke a state of long-term antigen-specific tolerance to some antigens. Why the effect is restricted to particular antigens, and the exact mechanisms of tolerance induction remain to be determined.

Animals↗

An increase in the survival of murine H-2-mismatched cultured fetal pancreas allografts using depleting or nondepleting anti-CD4 monoclonal antibodies, and a further increase with the addition of cyclosporine.

Depletion of CD4+ T lymphocytes with monoclonal antibodies (mAbs) has been shown to prolong allograft survival in mice. In this study, two rat anti-CD4 mAbs, H129.19 and GK1.5, were administered either alone or in combination with cyclosporine (CsA) to recipients of MHC-mismatched (H-2k to H-2d) cultured fetal pancreas allografts to determine their effect on graft survival. When compared with control mice, splenic CD4+ cells of GK1.5-treated mice were depleted by greater than 95%, but in H129.19-treated mice no depletion of CD4+ cells occurred. Instead, rat Ig was present on the surface of CD4+ cells in H129.19-treated mice. Anti-CD4 therapy with either H129.19 or GK1.5 prolonged fetal pancreas allograft survival to a similar extent, but did not lead to indefinite survival. Blockade of the CD4 antigen by the mAb H129.19 was as effective as the depletion of CD4+ cells by GK1.5 in prolonging allograft survival. Rejection of grafts by day 28 posttransplantation occurred in the absence of CD4+ cells, as determined by both flow cytometric examination of spleen cells and immunoperoxidase staining of the graft site. CsA alone did not prolong graft survival, but its addition to either H129.19 or GK1.5 mAb treatment significantly increased the survival rate of grafts at 28 days compared with mAb treatment alone. These results suggest that CD4+ cell depletion is not essential for effective anti-CD4 mAb therapy--and, further, that CsA may have a direct inhibitory effect on CD8+ cells during allograft rejection.

Animals↗

Difference in effect of cultured fetal pancreas transplants on retinal and renal capillary basement membrane thickness in diabetic mice.

The goal of endocrine pancreas transplants should be the prevention of diabetic complications. The differential effect of grafts of organ-cultured fetal mouse pancreas on diabetic complications in the retina and kidney was tested by comparing capillary basement membrane thickness (BMT) in mice made diabetic with streptozotocin and transplanted either early or late, or treated with insulin. BALB/c female mice were grafted with a single organ-cultured syngeneic fetal pancreas at either 3 weeks or 7 months after induction of diabetes. Controls were sex- and age-matched nondiabetic; diabetic untreated; and diabetic insulin-treated mice. All mice were killed at 20 months of age and their eyes and kidneys fixed for electron microscopy. BMT was measured on coded micrographs. In all mice glomerular capillary BM were thicker than retinal capillary BM. Mice grafted early after the induction of diabetes had normal BMT in both sites, while those transplanted after 6 months of disease had normal retinal, but thickened glomerular, capillary BM. In each case the late-transplanted animals had BM thickness significantly less than the insulin-treated or untreated diabetics.

Animals↗

Comparison of high- and low-diabetes-incidence NOD mouse strains.

The nonobese diabetic (NOD) mouse is a model of insulin-dependent diabetes mellitus. These mice develop insulinopenia and hyperglycemia secondary to beta-cell destruction, which is associated with insulitis and autoantibody production. We have two strains of NOD mice: a low-incidence strain (NOD/Wehi), in which less than 10% females and less than 1% males develop diabetes by 150 days despite intense insulitis, and a high-incidence strain (NOD/Lt), in which most females and many males develop diabetes by 150 days. This phenotypic difference has been maintained for 24 mo despite identical housing in our specific pathogen-free unit. Reciprocal skin grafting and allozyme electrophoresis have not identified a difference between the strains. Mixed-lymphocyte cultures were performed with splenic T-lymphocytes cultured with equal numbers of irradiated stimulator splenocytes for 3-6 days. NOD/Wehi mice demonstrated a heightened syngeneic mixed-lymphocyte response (SMLR), averaging 19% of the allogeneic response to CBA/CaHWehi cells. The response to NOD/Lt stimulator cells was not significantly different from the syngeneic response. In contrast, NOD/Lt mice had an SMLR similar to that of BALB/cAnBradleyWehi control mice, averaging 5% of the allogeneic response. NOD/Lt cells also responded similarly to NOD/Wehi stimulator cells and briskly to allogeneic cells. The heightened SMLR in NOD/Wehi mice may reflect active generation of suppressor function, and this may account for the low incidence of diabetes.

Alleles↗

Prevention of cyclophosphamide-induced diabetes by anti-V beta 8 T-lymphocyte-receptor monoclonal antibody therapy in NOD/Wehi mice.

Walter & Eliza Hall Institute nonobese diabetic (NOD/Wehi) mice exhibit a low incidence of spontaneous diabetes mellitus, but one large dose of cyclophosphamide (CY) can lead to a rapid progression to overt diabetes. Macrophages and Lyt-2+ and L3T4+ cells have been demonstrated to be involved in beta-cell destruction in this model. The role of a specific subset of T-lymphocytes expressing a particular T-lymphocyte-receptor segment was examined in CY-induced diabetic NOD mice with a mouse anti-V beta 8 T-lymphocyte-receptor monoclonal antibody (F23.1). After administration of CY, only 4 of 51 treated mice became hyperglycemic compared to 23 of 47 untreated mice, 13 of 26 mice treated with an isotype-matched control ascites, and 4 of 6 mice given antibody-negative ascites. Insulitis was significantly reduced in the F23.1-treated group, and immunocytochemistry revealed the absence of V beta 8 expression on cells in the lymphoid organs and insulitis of these mice. This investigation revealed that V beta 8+ cells were implicated in CY-induced diabetes in NOD/Wehi mice.

Animals↗

Cyclophosphamide-induced diabetes in NOD/WEHI mice. Evidence for suppression in spontaneous autoimmune diabetes mellitus.

Nonobese diabetic (NOD) mice spontaneously develop a lymphocytic infiltration of pancreatic islets (insulitis) that may progress to overt diabetes. Virtually all NOD/WEHI mice develop insulitis, but very few progress to diabetes. However, cyclophosphamide (CY) can promote the onset of diabetes in NOD mice, including the NOD/WEHI strain. The means by which CY produces diabetes was investigated in NOD/WEHI mice, in which it was hypothesized that active suppression mechanisms prevented the progression from insulitis to diabetes. A study of the time course of insulitis in the islets after CY was given showed that insulitis was initially reduced but rapidly increased over 16 days, and T-lymphocytes were predominant in the lesion. This suggested a compression of the normal time course of the disease seen in NOD mice. CY did not produce diabetes in any of 11 non-NOD strains studied. Fetal isografts in NOD mice given CY several days before were subjected to lymphocytic infiltration and beta-cell destruction. These findings suggested that CY was not directly beta-cell toxic and that altered beta-cells were not essential for beta-cell destruction. This was further demonstrated with subdiabetogenic doses of streptozocin, which significantly damaged beta-cells but did not increase the severity of insulitis or induce diabetes as did CY. Most important, the transfer of mononuclear cells from nondiabetic NOD mice to mice given CY prevented diabetes, which indicated that the likely effect of CY was via immunomodulation, possibly by allowing poised effector cells to act on beta-cells.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗